On the public citation graph

Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors

0 signed · 49 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ijc.31220openalex-snapshot

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance

inferredcites →https://doi.org/10.1002/jcb.27808openalex-snapshot

Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAFV600E mutation

inferredcites →https://doi.org/10.1002/jcp.25850openalex-snapshot

The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells

inferredcites →https://doi.org/10.1016/j.bbrc.2017.06.092openalex-snapshot

The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization

inferredcites →https://doi.org/10.1016/j.biopha.2019.108967openalex-snapshot

Qing Chang Hua Shi granule ameliorate inflammation in experimental rats and cell model of ulcerative colitis through MEK/ERK signaling pathway

inferredcites →https://doi.org/10.1016/j.canlet.2016.02.045openalex-snapshot

Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression

inferredcites →https://doi.org/10.1016/j.canlet.2017.05.015openalex-snapshot

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer

inferredcites →https://doi.org/10.1016/j.canlet.2017.05.017openalex-snapshot

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF -mutant colon cancer cells via repression of MAPK signaling pathway

inferredcites →https://doi.org/10.1016/j.ccell.2018.11.006openalex-snapshot

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

inferredcites →https://doi.org/10.1016/j.celrep.2015.03.015openalex-snapshot

Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZ

inferredcites →https://doi.org/10.1016/j.jhep.2009.02.027openalex-snapshot

Protein kinase SGK1 enhances MEK/ERK complex formation through the phosphorylation of ERK2: Implication for the positive regulatory role of SGK1 on the ERK function during liver regeneration

inferredcites →https://doi.org/10.1016/j.tranon.2020.100795openalex-snapshot

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

inferredcites →https://doi.org/10.1038/nature10868openalex-snapshot

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

inferredcites →https://doi.org/10.1038/ng.3218openalex-snapshot

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

inferredcites →https://doi.org/10.1038/onc.2017.120openalex-snapshot

Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer

inferredcites →https://doi.org/10.1038/onc.2017.384openalex-snapshot

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

inferredcites →https://doi.org/10.1038/s41419-018-0698-3openalex-snapshot

miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP

inferredcites →https://doi.org/10.1042/bj20141005openalex-snapshot

Hepatic serum- and glucocorticoid-regulated protein kinase 1 (SGK1) regulates insulin sensitivity in mice via extracellular-signal-regulated kinase 1/2 (ERK1/2)

inferredcites →https://doi.org/10.1056/nejmoa1908075openalex-snapshot

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

inferredcites →https://doi.org/10.1074/jbc.rev119.007963openalex-snapshot

Control of cellular responses to mechanical cues through YAP/TAZ regulation

inferredcites →https://doi.org/10.1080/15384101.2015.1032644openalex-snapshot

YAP in MAPK pathway targeted therapy resistance

inferredcites →https://doi.org/10.1080/23723556.2015.1021441openalex-snapshot

The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors

inferredcites →https://doi.org/10.1111/pcmr.12211openalex-snapshot

Cyclin‐dependent kinases as therapeutic targets in melanoma

inferredcites →https://doi.org/10.1111/pcmr.12742openalex-snapshot

Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer

inferredcites →https://doi.org/10.1158/0008-5472.can-12-3793openalex-snapshot

YAP/TEAD–Mediated Transcription Controls Cellular Senescence

inferredcites →https://doi.org/10.1158/0008-5472.can-17-1767openalex-snapshot

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells

inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-0665openalex-snapshot

Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

inferredcites →https://doi.org/10.1158/1541-7786.mcr-17-0404openalex-snapshot

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer

inferredcites →https://doi.org/10.1158/2159-8290.cd-17-1226openalex-snapshot

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

inferredcites →https://doi.org/10.1158/2159-8290.cd-18-0125openalex-snapshot

Advances on the BRAF Front in Colorectal Cancer

inferredcites →https://doi.org/10.1158/2159-8290.cd-18-0224openalex-snapshot

Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges

inferredcites →https://doi.org/10.1159/000354486openalex-snapshot

Inhibition of Colonic Tumor Growth by the Selective SGK Inhibitor EMD638683

inferredcites →https://doi.org/10.15252/embj.201593584openalex-snapshot

Eradicating tumor drug resistance at its YAP‐biomechanical roots

inferredcites →https://doi.org/10.3322/caac.21387openalex-snapshot

Cancer statistics, 2017

inferredcites →https://doi.org/10.3322/caac.21395openalex-snapshot

Colorectal cancer statistics, 2017

inferredcites →https://doi.org/10.3390/ijms18071527openalex-snapshot

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

inferredcites →https://doi.org/10.3748/wjg.v21.i20.6180openalex-snapshot

SGK1 inhibits cellular apoptosis and promotes proliferationviathe MEK/ERK/p53 pathway in colitis

inferredcites →https://doi.org/10.3892/or.2018.6630openalex-snapshot

Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells

inferredcites →https://doi.org/10.5483/bmbrep.2018.51.3.018openalex-snapshot

Clinical implications of the Hippo-YAP pathway in multiple cancer contexts

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3940635openalex-extracted

Capicua Suppresses YAP1 To Limit Tumorigenesis and Maintain Drug Sensitivity in Human Cancer

inferred← citeshttps://doi.org/10.1002/jcb.30517openalex-snapshot

The rational modulation of autophagy sensitizes colorectal cancer cells to 5‐fluouracil and oxaliplatin

inferred← citeshttps://doi.org/10.1007/s44371-026-00562-3openalex-snapshot

Dual targeting of YAP1 and β-catenin: a therapeutic strategy for colorectal cancer

inferred← citeshttps://doi.org/10.1016/j.celrep.2022.111443openalex-snapshot

Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer

inferred← citeshttps://doi.org/10.1016/j.drup.2026.101387openalex-snapshot

Programmed cell death network in cancer drug resistance: A framework for therapeutic intervention

inferred← citeshttps://doi.org/10.1038/s41598-023-50443-3openalex-snapshot

Characterization of dabrafenib-induced drug insensitivity via cellular barcoding and collateral sensitivity to second-line therapeutics

inferred← citeshttps://doi.org/10.3390/cancers16050852openalex-snapshot

Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD

inferred← citeshttps://doi.org/10.3390/cells10102715openalex-snapshot

Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine

inferred← citeshttps://doi.org/10.3390/pharmaceutics14020391openalex-snapshot

Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library

inferred← citeshttps://doi.org/10.7150/ijbs.83586openalex-snapshot

Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.